W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Eric J. Small,Susan Halabi,Nancy A. Dawson,Walter M. Stadler,Brian I. Rini,Joel Picus,Preston Gable,Frank M. Torti,Ellen B. Kaplan,Nicholas J. Vogelzang +9 more
TL;DR: The therapeutic effect of antiandrogen withdrawal alone was compared with simultaneous AAWD and K therapy in AiPCa patients as mentioned in this paper, with no difference in survival between the two groups.
Journal ArticleDOI
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
Naomi B. Haas,Judith Manola,Robert G. Uzzo,Keith T. Flaherty,Christopher G. Wood,Christopher J. Kane,Michael A.S. Jewett,Janice P. Dutcher,Michael B. Atkins,Michael R. Pins,G. Wilding,David Cella,Lynne I. Wagner,Surena F. Matin,Timothy M. Kuzel,Wade J. Sexton,Yu-Ning Wong,Toni K. Choueiri,Roberto Pili,Igor Puzanov,Manish Kohli,Walter M. Stadler,Michael A. Carducci,Robert Coomes,Robert S. DiPaola +24 more
TL;DR: Sunitinib and sorafenib, two oral anti-angiogenic agents that are effective in advanced renal-cell carcinoma, are tested in patients with resected local disease at high risk for recurrence in a double-blind, placebo-controlled, randomised, phase 3 trial.
Journal ArticleDOI
Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells
Henry K. Lin,Siyang Zheng,Anthony Williams,Marija Balic,Susan Groshen,Howard I. Scher,Martin Fleisher,Walter M. Stadler,Ram H. Datar,Yu-Chong Tai,Richard J. Cote +10 more
TL;DR: A novel parylene membrane filter-based portable microdevice for size-based isolation with high recovery rate and direct on-chip characterization of captured CTC from human peripheral blood has the potential to enable routine CTC analysis in the clinical setting for the effective management of cancer patients.
Journal ArticleDOI
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Hedy L. Kindler,Gregory Friberg,D. A. Singh,Gershon Y. Locker,Sreenivasa Nattam,Mark Kozloff,David A. Taber,Theodore Karrison,Abraham H. Dachman,Walter M. Stadler,Everett E. Vokes +10 more
TL;DR: The combination of bevacizumab plus gemcitabine is active in advanced pancreatic cancer patients, and the response rate and overall survival of patients who received gem citabine with the recombinant humanized anti-VEGF monoclonal antibody was assessed.
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly,Susan Halabi,Michael A. Carducci,Daniel J. George,John Francis Mahoney,Walter M. Stadler,Michael J. Morris,Philip W. Kantoff,J. Paul Monk,Ellen B. Kaplan,Nicholas J. Vogelzang,Eric J. Small +11 more
TL;DR: Despite an improvement in PFS and OR, the addition of bevacizumab to docetaxel and prednisone did not improve OS in men with mCRPC and was associated with greater toxicity.